Cargando…

Radiomic study on preoperative multi‐modal magnetic resonance images identifies IDH‐mutant TERT promoter‐mutant gliomas

OBJECTIVES: Gliomas with comutations of isocitrate dehydrogenase (IDH) genes and telomerase reverse transcriptase (TERT) gene promoter (IDHmut pTERTmut) show distinct biological features and respond to first‐line treatment differently in comparison with other gliomas. This study aimed to characteriz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haoyu, Zhang, Shuxin, Xing, Xiang, Yue, Qiang, Feng, Wentao, Chen, Siliang, Zhang, Jun, Xie, Dan, Chen, Ni, Liu, Yanhui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939206/ https://www.ncbi.nlm.nih.gov/pubmed/36176070 http://dx.doi.org/10.1002/cam4.5097

Ejemplares similares

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Stalled oligodendrocyte differentiation in IDH-mutant gliomas
por: Wei, Yanfei, et al.
Publicado: (2023)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

MPC-2 Clinical course and prognosis of lower-grade glioma, IDH wildtype and pTERT mutant
por: Takahashi, Yoshinobu, et al.
Publicado: (2021)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Updates on the WHO diagnosis of IDH-mutant glioma
por: Reuss, David.E.
Publicado: (2023)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

Mutant IDH1 Promotes Glioma Formation In Vivo
por: Philip, Beatrice, et al.
Publicado: (2018)

Epigenetic Reprogramming for Targeting IDH-Mutant Malignant Gliomas
por: Park, Jong-Whi, et al.
Publicado: (2019)

Malignant Progression of an IDH Mutant Brainstem Glioma in Adult
por: SANO, Kenshi, et al.
Publicado: (2021)

Proteome-based insights for IDH-mutant glioma classification
por: Leu, Severina, et al.
Publicado: (2023)

Mutant IDH in Gliomas: Role in Cancer and Treatment Options
por: Solomou, Georgios, et al.
Publicado: (2023)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

Nuclear Magnetic Resonance Metabolic Fingerprint of Bevacizumab in Mutant IDH1 Glioma Cells
por: Mesti, Tanja, et al.
Publicado: (2018)

METABOLOGENOMIC CHARACTERIZATION UNCOVERS HETEROGENEITY AMONG IDH MUTANT GLIOMAS
por: Ajisebutu, Andrew, et al.
Publicado: (2023)

Lesion location implemented magnetic resonance imaging radiomics for predicting IDH and TERT promoter mutations in grade II/III gliomas
por: Arita, Hideyuki, et al.
Publicado: (2018)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

LGG-03. INCIDENCE AND OUTCOME OF PEDIATRIC IDH-MUTANT GLIOMA
por: Yeo, Kee Kiat, et al.
Publicado: (2020)

Early Noninvasive Metabolic Biomarkers of Mutant IDH Inhibition in Glioma
por: Radoul, Marina, et al.
Publicado: (2021)

CBMS-1 TARGETING GLUTAMINE METABOLISM IN IDH-MUTANT GLIOMAS
por: Ohba, Shigeo, et al.
Publicado: (2022)

Radiotherapy delays malignant transformation and prolongs survival in patients with IDH-mutant gliomas
por: Liu, Yanwei, et al.
Publicado: (2022)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

IGFBP2 expression predicts IDH-mutant glioma patient survival
por: Huang, Lin Eric, et al.
Publicado: (2016)

Mutant IDH1 regulates the tumor-associated immune system in gliomas
por: Amankulor, Nduka M., et al.
Publicado: (2017)

Increased Radiation-Associated T-Cell Infiltration in Recurrent IDH-Mutant Glioma
por: Makarevic, Anastasia, et al.
Publicado: (2020)

IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice
por: Richardson, Leland G., et al.
Publicado: (2020)

A vaccine targeting mutant IDH1 in newly diagnosed glioma
por: Platten, Michael, et al.
Publicado: (2021)

IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat
por: Sears, Thomas K., et al.
Publicado: (2021)

ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma
por: Babikir, Husam, et al.
Publicado: (2021)

Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas
por: Ferreyra Vega, Sandra, et al.
Publicado: (2023)

Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas
por: Wollring, Michael M., et al.
Publicado: (2022)

The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma
por: Javier, Rodrigo, et al.
Publicado: (2022)

Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes
por: Pathmanapan, Sinthu, et al.
Publicado: (2021)

Case Report: Clinicopathological and Genetic Features of IDH-Mutant Brainstem Glioma in Adults: Report of Five Cases
por: Zhou, Jiangfen, et al.
Publicado: (2022)

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma
por: Fanucci, Kristina, et al.
Publicado: (2023)

Induction of sarcomas by mutant IDH2
por: Lu, Chao, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_h92b3p242fad07ve5comsjnlfk